Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
2,108
archived clinical trials in
Lupus

Pediatric Lupus Trial of Belimumab Plus Background Standard Therapy
A Multi-center, Randomized, Placebo-Controlled Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of Belimumab, a Human Monoclonal Anti-BLyS Antibody, Plus Standard Therapy in Pediatric Patients With Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Lake Success, NY
Pediatric Lupus Trial of Belimumab Plus Background Standard Therapy
A Multi-center, Randomized, Placebo-Controlled Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of Belimumab, a Human Monoclonal Anti-BLyS Antibody, Plus Standard Therapy in Pediatric Patients With Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Lake Success, NY
Click here to add this to my saved trials
Pediatric Lupus Trial of Belimumab Plus Background Standard Therapy
A Multi-center, Randomized, Placebo-Controlled Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of Belimumab, a Human Monoclonal Anti-BLyS Antibody, Plus Standard Therapy in Pediatric Patients With Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Cincinnati, OH
Pediatric Lupus Trial of Belimumab Plus Background Standard Therapy
A Multi-center, Randomized, Placebo-Controlled Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of Belimumab, a Human Monoclonal Anti-BLyS Antibody, Plus Standard Therapy in Pediatric Patients With Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Pediatric Lupus Trial of Belimumab Plus Background Standard Therapy
A Multi-center, Randomized, Placebo-Controlled Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of Belimumab, a Human Monoclonal Anti-BLyS Antibody, Plus Standard Therapy in Pediatric Patients With Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Houston, TX
Pediatric Lupus Trial of Belimumab Plus Background Standard Therapy
A Multi-center, Randomized, Placebo-Controlled Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of Belimumab, a Human Monoclonal Anti-BLyS Antibody, Plus Standard Therapy in Pediatric Patients With Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Houston, TX
Click here to add this to my saved trials
Pediatric Lupus Trial of Belimumab Plus Background Standard Therapy
A Multi-center, Randomized, Placebo-Controlled Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of Belimumab, a Human Monoclonal Anti-BLyS Antibody, Plus Standard Therapy in Pediatric Patients With Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Rosario,
Pediatric Lupus Trial of Belimumab Plus Background Standard Therapy
A Multi-center, Randomized, Placebo-Controlled Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of Belimumab, a Human Monoclonal Anti-BLyS Antibody, Plus Standard Therapy in Pediatric Patients With Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Rosario,
Click here to add this to my saved trials
Pediatric Lupus Trial of Belimumab Plus Background Standard Therapy
A Multi-center, Randomized, Placebo-Controlled Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of Belimumab, a Human Monoclonal Anti-BLyS Antibody, Plus Standard Therapy in Pediatric Patients With Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Boston, MA
Pediatric Lupus Trial of Belimumab Plus Background Standard Therapy
A Multi-center, Randomized, Placebo-Controlled Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of Belimumab, a Human Monoclonal Anti-BLyS Antibody, Plus Standard Therapy in Pediatric Patients With Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Boston, MA
Click here to add this to my saved trials
Pediatric Lupus Trial of Belimumab Plus Background Standard Therapy
A Multi-center, Randomized, Placebo-Controlled Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of Belimumab, a Human Monoclonal Anti-BLyS Antibody, Plus Standard Therapy in Pediatric Patients With Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
New York, NY
Pediatric Lupus Trial of Belimumab Plus Background Standard Therapy
A Multi-center, Randomized, Placebo-Controlled Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of Belimumab, a Human Monoclonal Anti-BLyS Antibody, Plus Standard Therapy in Pediatric Patients With Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
New York, NY
Click here to add this to my saved trials
Pediatric Lupus Trial of Belimumab Plus Background Standard Therapy
A Multi-center, Randomized, Placebo-Controlled Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of Belimumab, a Human Monoclonal Anti-BLyS Antibody, Plus Standard Therapy in Pediatric Patients With Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Bronx, NY
Pediatric Lupus Trial of Belimumab Plus Background Standard Therapy
A Multi-center, Randomized, Placebo-Controlled Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of Belimumab, a Human Monoclonal Anti-BLyS Antibody, Plus Standard Therapy in Pediatric Patients With Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Bronx, NY
Click here to add this to my saved trials
Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BMS-188667 (Abatacept) or Placebo on a Background of Mycophenolate Mofetil and Corticosteroids in the Treatment of Subjects With Active Class III or IV Lupus Nephritis
Status: Enrolling
Updated:  12/31/1969
University of Alabama at Birmingham (UAB)
mi
from
Birmingham, AL
Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BMS-188667 (Abatacept) or Placebo on a Background of Mycophenolate Mofetil and Corticosteroids in the Treatment of Subjects With Active Class III or IV Lupus Nephritis
Status: Enrolling
Updated: 12/31/1969
University of Alabama at Birmingham (UAB)
mi
from
Birmingham, AL
Click here to add this to my saved trials
Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BMS-188667 (Abatacept) or Placebo on a Background of Mycophenolate Mofetil and Corticosteroids in the Treatment of Subjects With Active Class III or IV Lupus Nephritis
Status: Enrolling
Updated:  12/31/1969
Valerius Med Group & Res Ctr Of Greater Long Beach, Inc.
mi
from
Long Beach, CA
Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BMS-188667 (Abatacept) or Placebo on a Background of Mycophenolate Mofetil and Corticosteroids in the Treatment of Subjects With Active Class III or IV Lupus Nephritis
Status: Enrolling
Updated: 12/31/1969
Valerius Med Group & Res Ctr Of Greater Long Beach, Inc.
mi
from
Long Beach, CA
Click here to add this to my saved trials
Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BMS-188667 (Abatacept) or Placebo on a Background of Mycophenolate Mofetil and Corticosteroids in the Treatment of Subjects With Active Class III or IV Lupus Nephritis
Status: Enrolling
Updated:  12/31/1969
East Bay Rheumatology Medical Group, Inc.
mi
from
San Leandro, CA
Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BMS-188667 (Abatacept) or Placebo on a Background of Mycophenolate Mofetil and Corticosteroids in the Treatment of Subjects With Active Class III or IV Lupus Nephritis
Status: Enrolling
Updated: 12/31/1969
East Bay Rheumatology Medical Group, Inc.
mi
from
San Leandro, CA
Click here to add this to my saved trials
Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BMS-188667 (Abatacept) or Placebo on a Background of Mycophenolate Mofetil and Corticosteroids in the Treatment of Subjects With Active Class III or IV Lupus Nephritis
Status: Enrolling
Updated:  12/31/1969
University of Connecticut Health Center
mi
from
Farmington, CT
Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BMS-188667 (Abatacept) or Placebo on a Background of Mycophenolate Mofetil and Corticosteroids in the Treatment of Subjects With Active Class III or IV Lupus Nephritis
Status: Enrolling
Updated: 12/31/1969
University of Connecticut Health Center
mi
from
Farmington, CT
Click here to add this to my saved trials
Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BMS-188667 (Abatacept) or Placebo on a Background of Mycophenolate Mofetil and Corticosteroids in the Treatment of Subjects With Active Class III or IV Lupus Nephritis
Status: Enrolling
Updated:  12/31/1969
University of Miami Miller School of Medicine
mi
from
Miami, FL
Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BMS-188667 (Abatacept) or Placebo on a Background of Mycophenolate Mofetil and Corticosteroids in the Treatment of Subjects With Active Class III or IV Lupus Nephritis
Status: Enrolling
Updated: 12/31/1969
University of Miami Miller School of Medicine
mi
from
Miami, FL
Click here to add this to my saved trials
Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BMS-188667 (Abatacept) or Placebo on a Background of Mycophenolate Mofetil and Corticosteroids in the Treatment of Subjects With Active Class III or IV Lupus Nephritis
Status: Enrolling
Updated:  12/31/1969
Integral Rheumatology & Immunology Specialists
mi
from
Plantation, FL
Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BMS-188667 (Abatacept) or Placebo on a Background of Mycophenolate Mofetil and Corticosteroids in the Treatment of Subjects With Active Class III or IV Lupus Nephritis
Status: Enrolling
Updated: 12/31/1969
Integral Rheumatology & Immunology Specialists
mi
from
Plantation, FL
Click here to add this to my saved trials
Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BMS-188667 (Abatacept) or Placebo on a Background of Mycophenolate Mofetil and Corticosteroids in the Treatment of Subjects With Active Class III or IV Lupus Nephritis
Status: Enrolling
Updated:  12/31/1969
Rush University Medical Center
mi
from
Chicago, IL
Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BMS-188667 (Abatacept) or Placebo on a Background of Mycophenolate Mofetil and Corticosteroids in the Treatment of Subjects With Active Class III or IV Lupus Nephritis
Status: Enrolling
Updated: 12/31/1969
Rush University Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BMS-188667 (Abatacept) or Placebo on a Background of Mycophenolate Mofetil and Corticosteroids in the Treatment of Subjects With Active Class III or IV Lupus Nephritis
Status: Enrolling
Updated:  12/31/1969
Ochsner Clinic Foundation
mi
from
Baton Rouge, LA
Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BMS-188667 (Abatacept) or Placebo on a Background of Mycophenolate Mofetil and Corticosteroids in the Treatment of Subjects With Active Class III or IV Lupus Nephritis
Status: Enrolling
Updated: 12/31/1969
Ochsner Clinic Foundation
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BMS-188667 (Abatacept) or Placebo on a Background of Mycophenolate Mofetil and Corticosteroids in the Treatment of Subjects With Active Class III or IV Lupus Nephritis
Status: Enrolling
Updated:  12/31/1969
Brigham and Women's Hosp
mi
from
Boston, MA
Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BMS-188667 (Abatacept) or Placebo on a Background of Mycophenolate Mofetil and Corticosteroids in the Treatment of Subjects With Active Class III or IV Lupus Nephritis
Status: Enrolling
Updated: 12/31/1969
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BMS-188667 (Abatacept) or Placebo on a Background of Mycophenolate Mofetil and Corticosteroids in the Treatment of Subjects With Active Class III or IV Lupus Nephritis
Status: Enrolling
Updated:  12/31/1969
Boston University Medical Center
mi
from
Boston, MA
Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BMS-188667 (Abatacept) or Placebo on a Background of Mycophenolate Mofetil and Corticosteroids in the Treatment of Subjects With Active Class III or IV Lupus Nephritis
Status: Enrolling
Updated: 12/31/1969
Boston University Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BMS-188667 (Abatacept) or Placebo on a Background of Mycophenolate Mofetil and Corticosteroids in the Treatment of Subjects With Active Class III or IV Lupus Nephritis
Status: Enrolling
Updated:  12/31/1969
Local Institution
mi
from
Camden, NJ
Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BMS-188667 (Abatacept) or Placebo on a Background of Mycophenolate Mofetil and Corticosteroids in the Treatment of Subjects With Active Class III or IV Lupus Nephritis
Status: Enrolling
Updated: 12/31/1969
Local Institution
mi
from
Camden, NJ
Click here to add this to my saved trials
Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BMS-188667 (Abatacept) or Placebo on a Background of Mycophenolate Mofetil and Corticosteroids in the Treatment of Subjects With Active Class III or IV Lupus Nephritis
Status: Enrolling
Updated:  12/31/1969
SUNY Downstate Medical Center
mi
from
Brooklyn, NY
Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BMS-188667 (Abatacept) or Placebo on a Background of Mycophenolate Mofetil and Corticosteroids in the Treatment of Subjects With Active Class III or IV Lupus Nephritis
Status: Enrolling
Updated: 12/31/1969
SUNY Downstate Medical Center
mi
from
Brooklyn, NY
Click here to add this to my saved trials
Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BMS-188667 (Abatacept) or Placebo on a Background of Mycophenolate Mofetil and Corticosteroids in the Treatment of Subjects With Active Class III or IV Lupus Nephritis
Status: Enrolling
Updated:  12/31/1969
Northshore Lij Health System
mi
from
Great Neck, NY
Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BMS-188667 (Abatacept) or Placebo on a Background of Mycophenolate Mofetil and Corticosteroids in the Treatment of Subjects With Active Class III or IV Lupus Nephritis
Status: Enrolling
Updated: 12/31/1969
Northshore Lij Health System
mi
from
Great Neck, NY
Click here to add this to my saved trials
Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BMS-188667 (Abatacept) or Placebo on a Background of Mycophenolate Mofetil and Corticosteroids in the Treatment of Subjects With Active Class III or IV Lupus Nephritis
Status: Enrolling
Updated:  12/31/1969
The Feinstein Institute for Medical Research
mi
from
Manhasset, NY
Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BMS-188667 (Abatacept) or Placebo on a Background of Mycophenolate Mofetil and Corticosteroids in the Treatment of Subjects With Active Class III or IV Lupus Nephritis
Status: Enrolling
Updated: 12/31/1969
The Feinstein Institute for Medical Research
mi
from
Manhasset, NY
Click here to add this to my saved trials
Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BMS-188667 (Abatacept) or Placebo on a Background of Mycophenolate Mofetil and Corticosteroids in the Treatment of Subjects With Active Class III or IV Lupus Nephritis
Status: Enrolling
Updated:  12/31/1969
Hospital for Special Surgery
mi
from
New York, NY
Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BMS-188667 (Abatacept) or Placebo on a Background of Mycophenolate Mofetil and Corticosteroids in the Treatment of Subjects With Active Class III or IV Lupus Nephritis
Status: Enrolling
Updated: 12/31/1969
Hospital for Special Surgery
mi
from
New York, NY
Click here to add this to my saved trials
Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BMS-188667 (Abatacept) or Placebo on a Background of Mycophenolate Mofetil and Corticosteroids in the Treatment of Subjects With Active Class III or IV Lupus Nephritis
Status: Enrolling
Updated:  12/31/1969
Local Institution
mi
from
New York, NY
Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BMS-188667 (Abatacept) or Placebo on a Background of Mycophenolate Mofetil and Corticosteroids in the Treatment of Subjects With Active Class III or IV Lupus Nephritis
Status: Enrolling
Updated: 12/31/1969
Local Institution
mi
from
New York, NY
Click here to add this to my saved trials
Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BMS-188667 (Abatacept) or Placebo on a Background of Mycophenolate Mofetil and Corticosteroids in the Treatment of Subjects With Active Class III or IV Lupus Nephritis
Status: Enrolling
Updated:  12/31/1969
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BMS-188667 (Abatacept) or Placebo on a Background of Mycophenolate Mofetil and Corticosteroids in the Treatment of Subjects With Active Class III or IV Lupus Nephritis
Status: Enrolling
Updated: 12/31/1969
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BMS-188667 (Abatacept) or Placebo on a Background of Mycophenolate Mofetil and Corticosteroids in the Treatment of Subjects With Active Class III or IV Lupus Nephritis
Status: Enrolling
Updated:  12/31/1969
Shanahan Rheum & Immunotherapy, Pllc
mi
from
Raleigh, NC
Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BMS-188667 (Abatacept) or Placebo on a Background of Mycophenolate Mofetil and Corticosteroids in the Treatment of Subjects With Active Class III or IV Lupus Nephritis
Status: Enrolling
Updated: 12/31/1969
Shanahan Rheum & Immunotherapy, Pllc
mi
from
Raleigh, NC
Click here to add this to my saved trials
Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BMS-188667 (Abatacept) or Placebo on a Background of Mycophenolate Mofetil and Corticosteroids in the Treatment of Subjects With Active Class III or IV Lupus Nephritis
Status: Enrolling
Updated:  12/31/1969
MetroHealth Med Ctr
mi
from
Cleveland, OH
Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BMS-188667 (Abatacept) or Placebo on a Background of Mycophenolate Mofetil and Corticosteroids in the Treatment of Subjects With Active Class III or IV Lupus Nephritis
Status: Enrolling
Updated: 12/31/1969
MetroHealth Med Ctr
mi
from
Cleveland, OH
Click here to add this to my saved trials
Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BMS-188667 (Abatacept) or Placebo on a Background of Mycophenolate Mofetil and Corticosteroids in the Treatment of Subjects With Active Class III or IV Lupus Nephritis
Status: Enrolling
Updated:  12/31/1969
Paramount Medical Research & Consulting, Llc
mi
from
Middleburg Heights, OH
Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BMS-188667 (Abatacept) or Placebo on a Background of Mycophenolate Mofetil and Corticosteroids in the Treatment of Subjects With Active Class III or IV Lupus Nephritis
Status: Enrolling
Updated: 12/31/1969
Paramount Medical Research & Consulting, Llc
mi
from
Middleburg Heights, OH
Click here to add this to my saved trials
Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BMS-188667 (Abatacept) or Placebo on a Background of Mycophenolate Mofetil and Corticosteroids in the Treatment of Subjects With Active Class III or IV Lupus Nephritis
Status: Enrolling
Updated:  12/31/1969
Rheumatology Consultants Pllc
mi
from
Knoxville, TN
Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BMS-188667 (Abatacept) or Placebo on a Background of Mycophenolate Mofetil and Corticosteroids in the Treatment of Subjects With Active Class III or IV Lupus Nephritis
Status: Enrolling
Updated: 12/31/1969
Rheumatology Consultants Pllc
mi
from
Knoxville, TN
Click here to add this to my saved trials
Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BMS-188667 (Abatacept) or Placebo on a Background of Mycophenolate Mofetil and Corticosteroids in the Treatment of Subjects With Active Class III or IV Lupus Nephritis
Status: Enrolling
Updated:  12/31/1969
U.T. Southwestern Medical Center
mi
from
Dallas, TX
Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BMS-188667 (Abatacept) or Placebo on a Background of Mycophenolate Mofetil and Corticosteroids in the Treatment of Subjects With Active Class III or IV Lupus Nephritis
Status: Enrolling
Updated: 12/31/1969
U.T. Southwestern Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BMS-188667 (Abatacept) or Placebo on a Background of Mycophenolate Mofetil and Corticosteroids in the Treatment of Subjects With Active Class III or IV Lupus Nephritis
Status: Enrolling
Updated:  12/31/1969
University Of Utah Hospital
mi
from
Salt Lake City, UT
Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BMS-188667 (Abatacept) or Placebo on a Background of Mycophenolate Mofetil and Corticosteroids in the Treatment of Subjects With Active Class III or IV Lupus Nephritis
Status: Enrolling
Updated: 12/31/1969
University Of Utah Hospital
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BMS-188667 (Abatacept) or Placebo on a Background of Mycophenolate Mofetil and Corticosteroids in the Treatment of Subjects With Active Class III or IV Lupus Nephritis
Status: Enrolling
Updated:  12/31/1969
Local Institution
mi
from
Charlottesville, VA
Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BMS-188667 (Abatacept) or Placebo on a Background of Mycophenolate Mofetil and Corticosteroids in the Treatment of Subjects With Active Class III or IV Lupus Nephritis
Status: Enrolling
Updated: 12/31/1969
Local Institution
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BMS-188667 (Abatacept) or Placebo on a Background of Mycophenolate Mofetil and Corticosteroids in the Treatment of Subjects With Active Class III or IV Lupus Nephritis
Status: Enrolling
Updated:  12/31/1969
Emory University
mi
from
Atlanta, GA
Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BMS-188667 (Abatacept) or Placebo on a Background of Mycophenolate Mofetil and Corticosteroids in the Treatment of Subjects With Active Class III or IV Lupus Nephritis
Status: Enrolling
Updated: 12/31/1969
Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BMS-188667 (Abatacept) or Placebo on a Background of Mycophenolate Mofetil and Corticosteroids in the Treatment of Subjects With Active Class III or IV Lupus Nephritis
Status: Enrolling
Updated:  12/31/1969
Tulane University School of Medicine
mi
from
New Orleans, LA
Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BMS-188667 (Abatacept) or Placebo on a Background of Mycophenolate Mofetil and Corticosteroids in the Treatment of Subjects With Active Class III or IV Lupus Nephritis
Status: Enrolling
Updated: 12/31/1969
Tulane University School of Medicine
mi
from
New Orleans, LA
Click here to add this to my saved trials
Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BMS-188667 (Abatacept) or Placebo on a Background of Mycophenolate Mofetil and Corticosteroids in the Treatment of Subjects With Active Class III or IV Lupus Nephritis
Status: Enrolling
Updated:  12/31/1969
Organizacion Medica De Investigacion S.A. (Omi)
mi
from
Capital Federal,
Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BMS-188667 (Abatacept) or Placebo on a Background of Mycophenolate Mofetil and Corticosteroids in the Treatment of Subjects With Active Class III or IV Lupus Nephritis
Status: Enrolling
Updated: 12/31/1969
Organizacion Medica De Investigacion S.A. (Omi)
mi
from
Capital Federal,
Click here to add this to my saved trials
Study to Determine if Gardasil Vaccine is Safe and Effective in Lupus Patients
Phase I, Safety and Immunogenicity of Gardasil® in Systemic Lupus Erythematosus.
Status: Enrolling
Updated:  12/31/1969
DCaTS-Clinical Research Center
mi
from
Detroit, MI
Study to Determine if Gardasil Vaccine is Safe and Effective in Lupus Patients
Phase I, Safety and Immunogenicity of Gardasil® in Systemic Lupus Erythematosus.
Status: Enrolling
Updated: 12/31/1969
DCaTS-Clinical Research Center
mi
from
Detroit, MI
Click here to add this to my saved trials
Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Anniston, AL
Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Anniston, AL
Click here to add this to my saved trials
Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Birmingham, AL
Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Birmingham, AL
Click here to add this to my saved trials
Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Huntsville, AL
Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Huntsville, AL
Click here to add this to my saved trials
Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Glendale, AZ
Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Glendale, AZ
Click here to add this to my saved trials
Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Mesa, AZ
Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Mesa, AZ
Click here to add this to my saved trials
Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Phoenix, AZ
Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Phoenix, AZ
Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Covina, CA
Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Covina, CA
Click here to add this to my saved trials
Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Fremont, CA
Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Fremont, CA
Click here to add this to my saved trials
Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Huntington Beach, CA
Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Huntington Beach, CA
Click here to add this to my saved trials
Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
La Mesa, CA
Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
La Mesa, CA
Click here to add this to my saved trials
Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Long Beach, CA
Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Long Beach, CA
Click here to add this to my saved trials
Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Los Angeles, CA
Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Murrieta, CA
Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Murrieta, CA
Click here to add this to my saved trials
Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Sacramento, CA
Belimumab Assessment of Safety in SLE
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Sacramento, CA
Click here to add this to my saved trials